Stock Track | Ardelyx (ARDX) Plummets 14.07% as Quarterly Results Disappoint

Stock Track

Feb 20, 2025

Shares of Ardelyx Inc. (ARDX) plunged 14.07% during Thursday's trading session, as the biopharmaceutical company reported disappointing financial results for the fourth quarter.

The company, which develops innovative therapies for cardiorenal diseases, failed to meet analysts' expectations for revenue and earnings. While Ardelyx managed to generate some revenue from its recently launched product, it was not enough to offset the significant research and development costs associated with its pipeline.

Analysts had anticipated Ardelyx would report progress on its lead drug candidate for chronic kidney disease, but the company provided little update on the clinical trials, raising concerns about potential delays or setbacks in the development program.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1130680276"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130680276\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130680276?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130680276","market":"us","top_or_hot":-1,"title":"Stock Track | Ardelyx (ARDX) Plummets 14.07% as Quarterly Results Disappoint","media":"Stock Track","content":"<p>Shares of Ardelyx Inc. (ARDX) plunged 14.07% during Thursday's trading session, as the biopharmaceutical company reported disappointing financial results for the fourth quarter.</p>\n\n<p>The company, which develops innovative therapies for cardiorenal diseases, failed to meet analysts' expectations for revenue and earnings. While Ardelyx managed to generate some revenue from its recently launched product, it was not enough to offset the significant research and development costs associated with its pipeline.</p>\n\n<p>Analysts had anticipated Ardelyx would report progress on its lead drug candidate for chronic kidney disease, but the company provided little update on the clinical trials, raising concerns about potential delays or setbacks in the development program.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ardelyx (ARDX) Plummets 14.07% as Quarterly Results Disappoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ardelyx (ARDX) Plummets 14.07% as Quarterly Results Disappoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-20 23:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Ardelyx Inc. (ARDX) plunged 14.07% during Thursday's trading session, as the biopharmaceutical company reported disappointing financial results for the fourth quarter.</p>\n\n<p>The company, which develops innovative therapies for cardiorenal diseases, failed to meet analysts' expectations for revenue and earnings. While Ardelyx managed to generate some revenue from its recently launched product, it was not enough to offset the significant research and development costs associated with its pipeline.</p>\n\n<p>Analysts had anticipated Ardelyx would report progress on its lead drug candidate for chronic kidney disease, but the company provided little update on the clinical trials, raising concerns about potential delays or setbacks in the development program.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"","article_id":"1130680276","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130680276","pubTimestamp":1740064361,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ardelyx Inc.  plunged 14.07% during Thursday's trading session, as the biopharmaceutical company reported disappointing financial results for the fourth quarter.The company, which develops innovative therapies for cardiorenal diseases, failed to meet analysts' expectations for revenue and earnings. While Ardelyx managed to generate some revenue from its recently launched product, it was not enough to offset the significant research and development costs associated with its pipeline.Ana","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx"},"translate_title":"股票赛道Ardelyx(ARDX)因季度业绩令人失望而暴跌14.07%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1},"content_text":"Shares of Ardelyx Inc. (ARDX) plunged 14.07% during Thursday's trading session, as the biopharmaceutical company reported disappointing financial results for the fourth quarter.\nThe company, which develops innovative therapies for cardiorenal diseases, failed to meet analysts' expectations for revenue and earnings. While Ardelyx managed to generate some revenue from its recently launched product, it was not enough to offset the significant research and development costs associated with its pipeline.\nAnalysts had anticipated Ardelyx would report progress on its lead drug candidate for chronic kidney disease, but the company provided little update on the clinical trials, raising concerns about potential delays or setbacks in the development program.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}